EU Local Number,Report Type,EV Gateway Receipt Date,Primary Source Qualification,Primary Source Country for Regulatory Purposes,Literature Reference,Patient Age Group,Patient Age Group (as per reporter),Parent Child Report,Patient Sex,Reaction List PT (Duration – Outcome - Seriousness Criteria),Suspect/interacting Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),ICSR Form
EU-EC-10018614845,Spontaneous,2024-12-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - B-cell lymphoma - Drug withdrawn - [98d - 1{DF} - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018614845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018595175,Spontaneous,2024-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Colitis (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018595175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018586865,Spontaneous,2024-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Lower respiratory tract infection (n/a - Recovered/Resolved - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma recurrent - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018586865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018574098,Spontaneous,2024-12-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Face oedema (n/a - Recovered/Resolved - ),<BR><BR>Rash (n/a - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - 20mg - Oral use]),<BR><BR>TEPKINLY 48 MG SOLUTION FOR INJECTION [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - 1{DF} - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018574098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018566239,Spontaneous,2024-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Disease progression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Unevaluable event (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),DEXAMETHASONE [DEXAMETHASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018566239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018566601,Spontaneous,2024-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Disease progression (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018566601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018543102,Spontaneous,2024-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,COVID-19 (n/a - Not Recovered/Not Resolved - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018543102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018543130,Spontaneous,2024-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,COVID-19 (n/a - Not Recovered/Not Resolved - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018543130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018544198,Spontaneous,2024-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Disease progression (n/a - Unknown - ),"DOXORUBICIN HYDROCHLORIDE [DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018544198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018531989,Spontaneous,2024-12-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chronic obstructive pulmonary disease (n/a - Unknown - ),<BR><BR>HIV infection (n/a - Unknown - ),<BR><BR>Respiratory distress (n/a - Fatal - Results in Death)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018531989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018536632,Spontaneous,2024-12-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Breast cancer (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hepatic cytolysis (n/a - Recovering/Resolving - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Lymphoma - Dose reduced - [n/a - 48mg - Intravenous use]),"[ALLOPURINOL] (C - n/a - Dose not changed - [n/a - 300mg - Oral use]),<BR><BR>[CALCIUM FOLINATE, FOLINIC ACID] (C - n/a - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - Dose not changed - [n/a - 2400mg - Oral use]),<BR><BR>[VALACICLOVIR HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - 2{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018536632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018495195,Spontaneous,2024-12-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Unknown - ),<BR><BR>Death (n/a - Fatal - Results in Death),<BR><BR>Delirium (n/a - Unknown - ),<BR><BR>Hospitalisation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Multiple organ dysfunction syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Palliative care (n/a - Unknown - ),<BR><BR>Sedation (n/a - Unknown - ),<BR><BR>Sepsis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Unknown - ),<BR><BR>Tumour ulceration (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 48mg - Subcutaneous use]),"[DEXAMETHASONE, DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - ),<BR><BR>[DIPHENHYDRAMINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - ),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018495195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018467372,Spontaneous,2024-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - Intravenous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018467372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018457941,Spontaneous,2024-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Febrile neutropenia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","APIXABAN [APIXABAN] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>PREGABALIN [PREGABALIN] (S - Product used for unknown indication - n/a - [74d - n/a - n/a - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [1d - 375mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOPLATIN] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [1d - 5mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - n/a - Unknown - [108d - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE] (S - Premedication - n/a - [1d - 2mg - n/a - More in ICSR]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - n/a - Unknown - [108d - n/a - n/a]),<BR><BR>[ERGOCALCIFEROL] (S - Product used for unknown indication - n/a - [70d - n/a - n/a - More in ICSR]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [3d - n/a - n/a - More in ICSR]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma stage I - n/a - [n/a - n/a - n/a]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [2d - 5mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma stage I - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (S - Premedication, Product used for unknown indication - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (S - Product used for unknown indication - n/a - [1d - 1000mg - n/a - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMETHOPRIM] (S - Product used for unknown indication - n/a - [n/a - n/a - n/a])","[MAGNESIUM SULFATE] (C - Product used for unknown indication - n/a - [1d - n/a - n/a]),<BR><BR>[METAMIZOLE] (C - Product used for unknown indication - n/a - [1d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - Product used for unknown indication - n/a - [4d - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - n/a - [4d - n/a - n/a]),<BR><BR>[PIPERACILLIN] (C - Product used for unknown indication - n/a - [4d - n/a - n/a]),<BR><BR>[TAZOBACTAM] (C - Product used for unknown indication - n/a - [4d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018457941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018452713,Spontaneous,2024-12-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Progressive multifocal leukoencephalopathy (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage IV - Not applicable - [647d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma stage IV - Not applicable - [10d - n/a - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage IV - Not applicable - [57d - 375mg/m2 - Intravenous use - More in ICSR])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS (II) GLYCINE SULFATE COMPLEX] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM PIDOLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TOLTERODINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018452713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018443307,Spontaneous,2024-12-02 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Not Specified,COVID-19 (n/a - Recovered/Resolved - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018443307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018438837,Spontaneous,2024-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal distension (n/a - Unknown - ),<BR><BR>Back pain (n/a - Unknown - ),<BR><BR>Cytokine release syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Death (n/a - Fatal - Results in Death),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Diffuse large B-cell lymphoma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - ),<BR><BR>Oedema peripheral (n/a - Unknown - ),<BR><BR>Pleural effusion (n/a - Unknown - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 48mg - Subcutaneous use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018438837&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018433316,Spontaneous,2024-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Febrile neutropenia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>[GEMCITABINE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - 1000mg/m2 - n/a]),<BR><BR>[OXALIPLATIN] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - 100mg/m2 - n/a])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - Prophylaxis - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>SEMAGLUTIDE [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE] (C - Premedication - n/a - [1d - 5mg - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Premedication - n/a - [1d - 16mg - n/a]),<BR><BR>[PARACETAMOL] (C - Premedication - n/a - [1d - 1000mg - Oral use]),<BR><BR>[SULFAMETHOXAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018433316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018434359,Spontaneous,2024-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Neutropenia (n/a - Unknown - ),TEPKINLY [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018434359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018428881,Spontaneous,2024-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"B-lymphocyte count decreased (n/a - Unknown - ),<BR><BR>Condition aggravated (n/a - Unknown - ),<BR><BR>Cytokine release syndrome (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),LONCASTUXIMAB TESIRINE [LONCASTUXIMAB TESIRINE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018428881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018429245,Spontaneous,2024-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Enterococcal bacteraemia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia klebsiella (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018429245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018417915,Spontaneous,2024-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal lymphadenopathy (n/a - Unknown - ),<BR><BR>Off label use (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Drug withdrawn - [n/a - .16mg - Subcutaneous use]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - Infection prophylaxis - n/a - [n/a - 400mg - Oral use]),<BR><BR>[CO-TRIMOXAZOLE, SULFAMETHOXAZOLE, TRIMETHOPRIM, TRIMETHOPRIM BP, SULFAMETHOXAZOLE BP] (C - Infection prophylaxis - n/a - [n/a - 960mg - Oral use]),<BR><BR>[DIMENHYDRINATE, DIMENHYDRINATE BP] (C - Product used for unknown indication - n/a - [n/a - 62mg - Intravenous use]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - 100mg - Intravenous use]),<BR><BR>[PREDNISOLONE] (C - Product used for unknown indication - n/a - [n/a - 100mg - Intravenous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018417915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018419785,Spontaneous,2024-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Anaemia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Unknown - [n/a - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Richter's syndrome - Unknown - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Richter's syndrome - Unknown - [n/a - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN HYDROCHLORIDE] (S - Richter's syndrome - Not applicable - [n/a - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Richter's syndrome - Not applicable - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Richter's syndrome - Not applicable - [n/a - n/a - Intravenous use])","ELIQUIS [APIXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>TOCILIZUMAB [TOCILIZUMAB] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>UROREC [SILODOSIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>[DIOSMECTITE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[FOSFOMYCIN, FOSFOMYCIN TROMETAMOL] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OXYGEN] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TROSPIUM, TROSPIUM CHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018419785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018412453,Spontaneous,2024-11-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Rhinovirus infection (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018412453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018379645,Spontaneous,2024-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Sarcoma of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018379645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018374830,Spontaneous,2024-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cytokine release syndrome (270min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cytokine release syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Febrile neutropenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Dose not changed - [n/a - .16mg - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Richter's syndrome - Unknown - [1d - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Richter's syndrome - Unknown - [1d - 750mg/m2 - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Richter's syndrome - Not applicable - [1d - 50mg/m2 - Intravenous use]),<BR><BR>[PREDNISONE] (S - Richter's syndrome - Drug withdrawn - [n/a - 100mg - Intravenous use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Richter's syndrome - Not applicable - [1d - 1.4mg/m2 - Intravenous use])","[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - Premedication - Unknown - [1d - 5mg - Intravenous use]),<BR><BR>[PARACETAMOL] (C - Premedication - Unknown - [n/a - 1g - Intravenous use - More in ICSR]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - 1g - Intravenous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018374830&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018367753,Spontaneous,2024-11-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,COVID-19 (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - .16mg - Subcutaneous use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018367753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018336200,Spontaneous,2024-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,COVID-19 pneumonia (22d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Drug withdrawn - [41d - 48mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Drug withdrawn - [21d - 20mg - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Drug withdrawn - [23d - 375mg/m2 - Intravenous use - More in ICSR])","[AMLODIPINE BESILATE, PERINDOPRIL ARGININE, ATORVASTATIN CALCIUM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AVOCADO OIL UNSAPONIFIABLES, SOYBEAN OIL UNSAPONIFIABLES, SOYA OIL, AVOCADO OIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BIOFLAVONOIDS, DIOSMIN, HESPERIDIN, MICRONISED PURIFIED FLAVONOIC FRACTION] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISULEPIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1mg - Intravenous use]),<BR><BR>[CLARITHROMYCIN, OMEPRAZOLE, OMEPRAZOLE SODIUM] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, PARACETAMOL, PARACETAMOL, ACETYLSALICYLIC ACID, CAFFEINE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (C - n/a - n/a - [n/a - 80mg - Intravenous use]),<BR><BR>[NADROPARIN, NADROPARIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [3d - 100mg - Oral use - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018336200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018327810,Spontaneous,2024-11-12 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Follicular lymphoma (n/a - Fatal - Results in Death, Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Follicular lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018327810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018330899,Spontaneous,2024-11-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"SARS-CoV-2 test positive (n/a - Recovered/Resolved - ),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018330899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018322625,Spontaneous,2024-11-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hyperphosphataemia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"DEXAMETHASONE [DEXAMETHASONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 16mg - Oral use]),<BR><BR>DOXORUBICIN HYDROCHLORIDE [DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 50mg/m2 - Intravenous use]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - .16mg - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 750mg/m2 - Intravenous use]),<BR><BR>[PREDNISOLONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [3d - 100mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 1.4mg/m2 - Intravenous use])","DEXAMETHASONE [DEXAMETHASONE] (C - Diffuse large B-cell lymphoma stage IV - n/a - [n/a - 16mg - n/a]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [205d - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [38d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [404d - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [54d - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [358d - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [46d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [177d - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [54d - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [177d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [35d - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [54d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018322625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018314699,Spontaneous,2024-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pneumonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>SARS-CoV-2 test positive (n/a - Recovered/Resolved - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018314699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018311521,Spontaneous,2024-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Infection (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 48mg - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 750mg/m2 - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 50mg/m2 - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [5d - 100mg - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 1.4mg/m2 - Intravenous use])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [11d - 8mg - Oral use - More in ICSR]),<BR><BR>PEGFILGRASTIM [PEGFILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE [UMECLIDINIUM BROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [549d - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [7d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [936d - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [792d - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICOTINE, NICOTINE BITARTRATE DIHYDRATE, NICOTINE RESINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [34d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1g - Oral use - More in ICSR]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - 50mg - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM GLYCEROPHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - n/a - [8d - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [879d - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018311521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018302158,Spontaneous,2024-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash maculo-papular (n/a - Recovered/Resolved - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - B-cell lymphoma - Drug withdrawn - [63d - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018302158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018304771,Spontaneous,2024-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Disease progression (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018304771&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018290532,Spontaneous,2024-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pneumonia (13d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [n/a - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [64d - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [64d - n/a - Intravenous use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [2d - 80mg - Intravenous use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use])","LONQUEX [LIPEGFILGRASTIM] (C - n/a - n/a - [22d - n/a - n/a]),<BR><BR>PRIVIGEN [HUMAN NORMAL IMMUNOGLOBULIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALIZAPRIDE] (C - n/a - n/a - [9d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [56d - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [76d - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [21d - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [52d - n/a - n/a]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HALOPERIDOL] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [105d - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [21d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [34d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [174d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018290532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018294634,Spontaneous,2024-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (5645min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypotension (1590min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Infection (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (949min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","CAELYX PEGYLATED LIPOSOMAL [DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - n/a - [1d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [5d - n/a - n/a - More in ICSR]),<BR><BR>[PREDNISOLONE] (S - Diffuse large B-cell lymphoma stage IV - n/a - [12d - n/a - n/a - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - n/a - [n/a - n/a - Intravenous use])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - Prophylaxis - n/a - [3d - n/a - Oral use - More in ICSR]),<BR><BR>PEGFILGRASTIM [PEGFILGRASTIM] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE [UMECLIDINIUM BROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [549d - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [7d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [936d - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [792d - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Premedication - n/a - [1d - n/a - Oral use]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICOTINE, NICOTINE BITARTRATE DIHYDRATE, NICOTINE RESINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Premedication - n/a - [1d - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Prophylaxis - n/a - [1d - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM GLYCEROPHOSPHATE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - n/a - [8d - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [879d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018294634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018284756,Spontaneous,2024-11-05 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Hypotension (n/a - Recovered/Resolved - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018284756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018286964,Spontaneous,2024-11-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Ageusia (n/a - Unknown - ),<BR><BR>Asthenia (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Neutropenia (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - .16mg - Subcutaneous use - More in ICSR]),[PREDNISOLONE] (C - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018286964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018289195,Spontaneous,2024-11-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cytokine release syndrome (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [n/a - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [n/a - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Unknown - [n/a - n/a - Intravenous use])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>PEGFILGRASTIM [PEGFILGRASTIM] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE [UMECLIDINIUM BROMIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - Unknown - [7d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[NICOTINE, NICOTINE BITARTRATE DIHYDRATE, NICOTINE RESINATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - Unknown - [8d - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018289195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018279357,Spontaneous,2024-11-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Escherichia sepsis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Febrile neutropenia (11d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gastric ulcer (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neutrophil count decreased (6d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Oesophagitis (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Staphylococcal bacteraemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Unknown - Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - n/a - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Richter's syndrome - n/a - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Richter's syndrome - n/a - [n/a - 750mg/m2 - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Richter's syndrome - n/a - [n/a - 50mg/m2 - Intravenous use]),<BR><BR>[PREDNISONE] (S - Richter's syndrome - n/a - [5d - 100mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Richter's syndrome - n/a - [n/a - 1.4mg/m2 - Intravenous use])","ACCOFIL [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DAPTOMYCIN [DAPTOMYCIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [n/a - 15mg - Intravenous use - More in ICSR]),<BR><BR>EPORATIO [EPOETIN THETA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN CALCIUM, EZETIMIBE, ATORVASTATIN, EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFTRIAXONE, CEFTRIAXONE SODIUM] (C - n/a - n/a - [n/a - 1g - Subcutaneous use - More in ICSR]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - n/a - n/a - [n/a - 5mg - Intravenous use - More in ICSR]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - 1g - Oral use]),<BR><BR>[PERINDOPRIL TERT-BUTYLAMINE, INDAPAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PIPERACILLIN, PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 100mg - Oral use - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018279357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018272003,Spontaneous,2024-11-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Respiratory failure (n/a - Fatal - Results in Death, Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 4mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018272003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018267467,Spontaneous,2024-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cardiac arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - ),<BR><BR>Oxygen saturation decreased (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018267467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018259508,Spontaneous,2024-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease progression (n/a - Fatal - Results in Death),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - .16mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018259508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018260190,Spontaneous,2024-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease progression (n/a - Fatal - Results in Death, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018260190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018248561,Spontaneous,2024-10-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cytokine release syndrome (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypotension (1d - Recovered/Resolved - ),<BR><BR>Hypoxia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (0d - Recovered/Resolved - )",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),"DEXAMETHASONE [DEXAMETHASONE] (C - Cytokine release syndrome - n/a - [4d - 10mg - Intravenous use]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - Seizure prophylaxis - n/a - [n/a - 500mg - Oral use]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrointestinal disorder prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>TOCILIZUMAB [TOCILIZUMAB] (C - Cytokine release syndrome - n/a - [1d - 500mg - Intravenous use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORPHENAMINE] (C - Prophylaxis - n/a - [n/a - 10mg - Intravenous use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Prophylaxis - n/a - [n/a - 80mg - Intravenous use]),<BR><BR>[PARACETAMOL] (C - Prophylaxis - n/a - [n/a - 1000mg - Intravenous use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Blood potassium decreased - n/a - [n/a - 600mg - Oral use]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[VALACICLOVIR] (C - Prophylaxis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018248561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018253744,Spontaneous,2024-10-29 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Pleural thickening (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018253744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018245379,Spontaneous,2024-10-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood lactate dehydrogenase increased (35h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Blood potassium increased (35h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Disease progression (n/a - Fatal - Results in Death),<BR><BR>Hyperphosphataemia (35h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - .16mg - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - 375mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - 750mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[DEXAMETHASONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 16mg - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - 50mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - 100mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - 1.4mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[ZOPICLONE] (S - n/a - Dose not changed - [54d - n/a - n/a])","FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [38d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [404d - n/a - n/a - More in ICSR]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [358d - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [46d - n/a - n/a - More in ICSR]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [177d - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - n/a - n/a - [30d - n/a - n/a - More in ICSR]),<BR><BR>[MORPHINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [784d - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [177d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [4d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018245379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018245693,Spontaneous,2024-10-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - ),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Recovered/Resolved - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018245693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018238329,Spontaneous,2024-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Cardiac failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease progression (n/a - Unknown - Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>POLATUZUMAB VEDOTIN [POLATUZUMAB VEDOTIN] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018238329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018238362,Spontaneous,2024-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Neutropenia (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018238362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018238587,Spontaneous,2024-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Disease progression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018238587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018229978,Spontaneous,2024-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - ),<BR><BR>Respiratory failure (n/a - Fatal - Results in Death)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018229978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018234583,Spontaneous,2024-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,COVID-19 (n/a - Recovered/Resolved - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018234583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018210751,Spontaneous,2024-10-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,COVID-19 (n/a - Unknown - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018210751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018212526,Spontaneous,2024-10-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>SARS-CoV-2 test positive (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018212526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018204434,Spontaneous,2024-10-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Febrile neutropenia (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma - Dose reduced - [n/a - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - B-cell lymphoma - Dose reduced - [21d - 20mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma - Dose reduced - [15d - 375mg/m2 - Intravenous use])","DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [8d - 20mg - Intravenous use]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [19d - n/a - n/a]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [23d - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [231d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM FOLINATE, CALCIUM LEVOFOLINATE, CALCIUM LEVOFOLINATE PENTAHYDRATE, FOLINIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - n/a - n/a - [n/a - 2mg - Oral use - More in ICSR]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [40d - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HUMAN NORMAL IMMUNOGLOBULIN, HUMAN NORMAL IMMUNOGLOBULIN (IV)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [456d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [8d - 1g - Intravenous use - More in ICSR]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [11d - 100mg - Oral use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018204434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018198601,Spontaneous,2024-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Recurrent cancer (n/a - Unknown - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018198601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018193013,Spontaneous,2024-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Skin toxicity (n/a - Unknown - ),TEPKINLY [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018193013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018189901,Spontaneous,2024-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Meningitis aseptic (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),TEPKINLY [EPCORITAMAB] (S - Chronic lymphocytic leukaemia - Not applicable - [140d - 96mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018189901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018190156,Spontaneous,2024-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injection site erythema (n/a - Recovering/Resolving - ),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018190156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018178434,Spontaneous,2024-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cytokine release syndrome (6990min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (24d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypokalaemia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypoxia (1765min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (31h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - n/a - [1d - 48mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [1d - 750mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [1d - 50mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage I - Unknown - [n/a - 100mg - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose reduced - [1d - 1.4mg/m2 - Intravenous use])","ELIQUIS [APIXABAN] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[CLEMASTINE, CLEMASTINE FUMARATE] (C - Premedication - n/a - [1d - n/a - Intravenous use]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [3d - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - n/a - [2d - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [1d - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Premedication - n/a - [1d - n/a - Oral use - More in ICSR]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018178434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018150842,Spontaneous,2024-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Immune effector cell-associated neurotoxicity syndrome (n/a - Recovered/Resolved - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018150842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018141885,Spontaneous,2024-10-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Meningitis aseptic (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),TEPKINLY [EPCORITAMAB] (S - Chronic lymphocytic leukaemia - Not applicable - [140d - 96mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018141885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018135642,Spontaneous,2024-10-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"C-reactive protein increased (n/a - Unknown - ),<BR><BR>Cytokine release syndrome (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fibrin D dimer increased (n/a - Unknown - ),<BR><BR>Haemoglobin decreased (n/a - Unknown - ),<BR><BR>Hypotension (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma - Unknown - [n/a - .16mg - n/a - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - B-cell lymphoma - Unknown - [n/a - n/a - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma - Unknown - [n/a - 375mg - Intravenous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (S - Product used for unknown indication - Unknown - [n/a - 100mg - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (S - Product used for unknown indication - Dose not changed - [n/a - 400mg - n/a]),<BR><BR>[ALLOPURINOL] (S - Product used for unknown indication - Unknown - [50d - 300mg - n/a - More in ICSR]),<BR><BR>[AMOXICILLIN, CLAVULANIC ACID] (S - Product used for unknown indication - Unknown - [n/a - 1g - n/a - More in ICSR]),<BR><BR>[OMEPRAZOLE] (S - Product used for unknown indication - Dose not changed - [n/a - 20mg - Oral use]),<BR><BR>[PARACETAMOL] (S - Product used for unknown indication - Unknown - [15d - 1g - n/a - More in ICSR]),<BR><BR>[PREDNISONE] (S - Product used for unknown indication - Unknown - [3d - 100mg - n/a - More in ICSR]),<BR><BR>[SODIUM FLUORIDE] (S - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (S - Product used for unknown indication - Unknown - [50d - n/a - n/a - More in ICSR])","[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE] (C - n/a - Unknown - [n/a - 5mg - Intravenous use]),<BR><BR>[DRIED FERROUS SULFATE, FERROUS SULFATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - Unknown - [15d - 80mg - Intravenous use - More in ICSR]),<BR><BR>[SODIUM FLUORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[VALGANCICLOVIR] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018135642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018123696,Spontaneous,2024-10-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Cytokine release syndrome (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018123696&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018121790,Spontaneous,2024-10-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Disease progression (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018121790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018122644,Spontaneous,2024-10-05 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Not Specified,Bacteraemia (n/a - Unknown - Caused/Prolonged Hospitalisation),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018122644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018112046,Spontaneous,2024-10-03 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Disease progression (n/a - Fatal - Results in Death, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018112046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018098362,Spontaneous,2024-10-01 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - ),<BR><BR>Pneumonia bacterial (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018098362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018088751,Spontaneous,2024-09-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018088751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018070438,Spontaneous,2024-09-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,SARS-CoV-2 test positive (n/a - Recovered/Resolved - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - .16mg - Subcutaneous use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018070438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018054567,Spontaneous,2024-09-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Confusional state (n/a - Unknown - ),<BR><BR>Neuroborreliosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - n/a]),"ELIQUIS [APIXABAN] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - ),<BR><BR>[CARVEDILOL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOTRIMAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - ),<BR><BR>[CORTISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - Product used for unknown indication - n/a - ),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[RETINOL, RETINOL PALMITATE, DEXPANTHENOL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[TIZANIDINE, TIZANIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018054567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018012831,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,COVID-19 (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018012831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018013214,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Bacterial infection (n/a - Recovered/Resolved - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018013214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018013706,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,COVID-19 (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018013706&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018014372,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cytokine release syndrome (n/a - Recovered/Resolved - Life Threatening),TEPKINLY [EPCORITAMAB] (S - Non-Hodgkin's lymphoma - Drug withdrawn - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018014372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018014400,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Atrial fibrillation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Electrocardiogram abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Non-Hodgkin's lymphoma - Dose not changed - [n/a - .16mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018014400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10018015670,Spontaneous,2024-09-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood immunoglobulin G decreased (n/a - Recovered/Resolved - ),<BR><BR>Hypogammaglobulinaemia (n/a - Recovered/Resolved - )",TEPKINLY [EPCORITAMAB] (S - Non-Hodgkin's lymphoma - Dose not changed - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10018015670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017993367,Spontaneous,2024-09-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Rash (n/a - Recovered/Resolved - ),TEPKINLY [EPCORITAMAB] (S - Follicular lymphoma - Unknown - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017993367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017983293,Spontaneous,2024-09-10 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Hyponatraemia (n/a - Recovering/Resolving - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017983293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017984438,Spontaneous,2024-09-10 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory tract infection (n/a - Unknown - Caused/Prolonged Hospitalisation)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017984438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017988602,Spontaneous,2024-09-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Immune effector cell-associated neurotoxicity syndrome (2d - Recovered/Resolved - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017988602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017980980,Spontaneous,2024-09-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017980980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017970330,Spontaneous,2024-09-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Amnesia (n/a - Unknown - ),<BR><BR>Confusional state (n/a - Unknown - ),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017970330&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017961448,Spontaneous,2024-09-05 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,COVID-19 (n/a - Recovered/Resolved - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017961448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017952823,Spontaneous,2024-09-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes virus infection (6d - Recovered/Resolved - ),<BR><BR>Pyrexia (7d - Recovered/Resolved - )",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - .8mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017952823&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017941389,Spontaneous,2024-09-02 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Adenovirus infection (65d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cytokine release syndrome (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 562.5mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 37.5mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [5d - 100mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 1.4mg/m2 - Intravenous use])","DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [8d - n/a - n/a]),<BR><BR>HYQVIA [HUMAN NORMAL IMMUNOGLOBULIN] (C - n/a - n/a - [n/a - 10g - Oral use]),<BR><BR>OSELTAMIVIR [OSELTAMIVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PEGFILGRASTIM [PEGFILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ZOLEDRONIC ACID [ZOLEDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [9d - 10mg - Oral use - More in ICSR]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [650d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [655d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [113d - n/a - Oral use - More in ICSR]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [33d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [8d - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [447d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017941389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017935725,Spontaneous,2024-08-30 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Disease progression (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017935725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017917129,Spontaneous,2024-08-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Enterococcal infection (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017917129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017920470,Spontaneous,2024-08-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Myocardial infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [32d - n/a - Intravenous use])","INHIXA [ENOXAPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [142d - n/a - n/a]),<BR><BR>[CHLORPHENAMINE] (C - n/a - n/a - [n/a - 10mg - Intravenous use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - n/a - [24d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017920470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017913929,Spontaneous,2024-08-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Gastrointestinal perforation (16d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [22d - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Dose reduced - [n/a - 493mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Dose reduced - [n/a - 33mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [3d - 25mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - Dose reduced - [n/a - 1.4mg/m2 - Intravenous use - More in ICSR])","ENOXAPARIN SODIUM [ENOXAPARIN SODIUM] (C - n/a - n/a - [233d - n/a - n/a]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [n/a - 100mg - Intravenous use]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [472d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [13d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUTYLSCOPOLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFIXIME TRIHYDRATE] (C - n/a - n/a - [13d - n/a - n/a]),<BR><BR>[CEFIXIME, CEFIXIME TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE] (C - n/a - n/a - [37d - n/a - n/a - More in ICSR]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [464d - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - n/a - [n/a - 80mg - Intravenous use - More in ICSR]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [37d - n/a - n/a - More in ICSR]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [3d - 100mg - Oral use - More in ICSR]),<BR><BR>[RABEPRAZOLE SODIUM] (C - n/a - n/a - [479d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE] (C - n/a - n/a - [472d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017913929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017887959,Spontaneous,2024-08-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cytokine release syndrome (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypoxia (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Stress cardiomyopathy (n/a - Recovered/Resolved - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),"APIXABAN [APIXABAN] (C - Thrombosis prophylaxis - n/a - [139d - n/a - Oral use]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - Cytokine release syndrome - n/a - [5d - n/a - n/a]),<BR><BR>LAMIVUDINE TEVA [LAMIVUDINE] (C - Antiviral prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>TOCILIZUMAB [TOCILIZUMAB] (C - Cytokine release syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Antiviral prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Steroid diabetes - n/a - [n/a - n/a - Oral use]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Antifungal prophylaxis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017887959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017879240,Spontaneous,2024-08-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Fatal - Results in Death),<BR><BR>Haemorrhage (n/a - Fatal - Results in Death),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Fatal - Results in Death),<BR><BR>Melaena (n/a - Fatal - Results in Death)",TEPKINLY [EPCORITAMAB] (S - B-cell small lymphocytic lymphoma - Drug withdrawn - [n/a - 48mg - Subcutaneous use - More in ICSR]),[LENALIDOMIDE] (C - n/a - n/a - [n/a - 7.5mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017879240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017854182,Spontaneous,2024-08-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Haemophilus infection (85d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage III - Drug withdrawn - [37d - 48mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma stage III - Unknown - [15d - 20mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage III - Unknown - [113d - 1400mg - Intravenous use - More in ICSR])","[ACETYLCYSTEINE] (C - n/a - n/a - [15d - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [28d - n/a - n/a]),<BR><BR>[NADROPARIN] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[RIBOFLAVIN SODIUM PHOSPHATE, CYANOCOBALAMIN, THIAMINE, FERROUS GLUCONATE, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a - [4d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017854182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017822812,Spontaneous,2024-08-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Necrotising colitis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Not Recovered/Not Resolved - Life Threatening)","DOXORUBICIN HYDROCHLORIDE [DOXORUBICIN HYDROCHLORIDE] (S - Richter's syndrome - Drug withdrawn - [n/a - 50mg/m2 - Intravenous use]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Drug withdrawn - [n/a - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Richter's syndrome - Drug withdrawn - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Richter's syndrome - Drug withdrawn - [n/a - 750mg/m2 - Intravenous use]),<BR><BR>[PREDNISONE] (S - Richter's syndrome - Drug withdrawn - [n/a - n/a - Oral use]),<BR><BR>[VINCRISTINE SULFATE] (S - Richter's syndrome - Drug withdrawn - [n/a - 1.4mg/m2 - Intravenous use])","CASPOFUNGIN [CASPOFUNGIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>FENTANYL [FENTANYL, FENTANYL CITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>INSULIN HUMAN [INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>MIDAZOLAM [MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PALONOSETRON [PALONOSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RASBURICASE [RASBURICASE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ROACTEMRA [TOCILIZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ZOLEDRONIC ACID [ZOLEDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLCYSTEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALBUMIN, HUMAN ALBUMIN SOLUTION, HUMAN SERUM ALBUMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMPHOTERICIN B] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM GLUCONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFTRIAXONE, CEFTRIAXONE SODIUM] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[CHLORPHENAMINE] (C - n/a - n/a - [8d - 10mg - Intravenous use]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYCLOPHOSPHAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DELORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - n/a - n/a - [12d - n/a - n/a]),<BR><BR>[DOXORUBICIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENOXAPARIN] (C - n/a - n/a - [10d - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[LEVOFLOXACIN] (C - n/a - n/a - [9d - n/a - n/a]),<BR><BR>[LEVOSULPIRIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LINEZOLID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM ASPARTATE, POTASSIUM ASPARTATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEROPENEM ANHYDROUS, MEROPENEM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>[NEOSTIGMINE METHYLSULFATE] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [8d - 1g - Oral use]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [13d - n/a - n/a]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CANRENOATE] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VANCOMYCIN, VANCOMYCIN HYDROCHLORIDE] (C - n/a - n/a - [10d - n/a - n/a]),<BR><BR>[VANCOMYCIN, VANCOMYCIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017822812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017775502,Spontaneous,2024-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytomegalovirus infection reactivation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - B-cell lymphoma - n/a - [n/a - 48mg - Subcutaneous use]),"ACTOS [PIOGLITAZONE, PIOGLITAZONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 45mg - Oral use]),<BR><BR>APIDRA [INSULIN GLULISINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>LAMIVUDINE [LAMIVUDINE] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - 40mg - Oral use]),<BR><BR>TOUJEO [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - 400mg - Oral use]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 300mg - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - 50mg - Oral use]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017775502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017760862,Spontaneous,2024-07-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Biliary obstruction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Transaminases increased (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017760862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017739908,Spontaneous,2024-07-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - ),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Recovering/Resolving - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017739908&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017735354,Spontaneous,2024-07-23 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bacterial sepsis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease progression (n/a - Fatal - Results in Death),<BR><BR>Liver disorder (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017735354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017711785,Spontaneous,2024-07-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - B-cell lymphoma - n/a - [n/a - n/a - Subcutaneous use]),"ACTOS [PIOGLITAZONE, PIOGLITAZONE HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 45mg - Oral use]),<BR><BR>APIDRA [INSULIN GLULISINE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>LAMIVUDINE [LAMIVUDINE] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - 40mg - Oral use]),<BR><BR>TOUJEO [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - 400mg - Oral use]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 300mg - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - 50mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - .4mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017711785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017665241,Spontaneous,2024-07-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Cytokine release syndrome (n/a - Recovered/Resolved - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017665241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017660464,Spontaneous,2024-07-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Thrombotic microangiopathy (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017660464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017630711,Spontaneous,2024-07-04 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - ),<BR><BR>Pneumonia (n/a - Recovered/Resolved - )",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017630711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017631345,Spontaneous,2024-07-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (4d - Recovered/Resolved - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - n/a]),"LEVETIRACETAM [LEVETIRACETAM] (C - Seizure prophylaxis - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Tachycardia - n/a - [98d - n/a - Oral use]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - Pain - n/a - [5d - 20mg - Intravenous use]),<BR><BR>[PANTOPRAZOLE] (C - Gastrointestinal disorder prophylaxis - n/a - [54d - 40mg - Intravenous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017631345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017611452,Spontaneous,2024-07-02 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Confusional state (n/a - Unknown - ),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Immune-mediated neuropathy (n/a - Unknown - ),<BR><BR>JC virus infection (n/a - Unknown - ),<BR><BR>Joint range of motion decreased (n/a - Unknown - ),<BR><BR>Lacunar stroke (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervous system disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuroborreliosis (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),"DEXAMETHASONE [DEXAMETHASONE] (C - Immune effector cell-associated neurotoxicity syndrome - n/a - [n/a - 10mg - n/a]),<BR><BR>KEPPRA [LEVETIRACETAM] (C - Prophylaxis - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017611452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017580716,Spontaneous,2024-06-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Abdominal infection (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Drug withdrawn - [n/a - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Dose not changed - [22d - 20mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Drug withdrawn - [15d - 375mg/m2 - Intravenous use - More in ICSR])","ACTRAPID [INSULIN HUMAN, INSULIN HUMAN (RDNA)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [n/a - 20mg - Intravenous use]),<BR><BR>DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM FOLINATE, FOLINIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - n/a - n/a - [n/a - 2mg - Oral use - More in ICSR]),<BR><BR>[DICLOFENAC, DICLOFENAC DIETHYLAMINE, DICLOFENAC EPOLAMINE, DICLOFENAC POTASSIUM, DICLOFENAC RESINATE, DICLOFENAC SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, TRAMADOL, TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1g - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [4d - 100mg - Oral use]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TINZAPARIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017580716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017585820,Spontaneous,2024-06-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cytokine release syndrome (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dehydration (16d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumocystis jirovecii infection (20d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Dose not changed - [22d - 48mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Drug withdrawn - [21d - 20mg - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Dose not changed - [29d - 375mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (S - Pneumocystis jirovecii infection - Not applicable - [17d - 160mg - Oral use])","DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SITAGLIPTIN [SITAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAMETHASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017585820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017566114,Spontaneous,2024-06-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bronchopulmonary aspergillosis (n/a - Unknown - ),TEPKINLY [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017566114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017553909,Spontaneous,2024-06-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Respiratory tract infection (n/a - Unknown - ),<BR><BR>Therapeutic product effect incomplete (n/a - Unknown - )",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017553909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017525457,Spontaneous,2024-06-15 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Diffuse large B-cell lymphoma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hepatic lesion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Spinal disorder (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017525457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017506625,Spontaneous,2024-06-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cytokine release syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease progression (n/a - Unknown - Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>GLOFITAMAB [GLOFITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 2.5mg - Intravenous use]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>TAFASITAMAB [TAFASITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017506625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017498120,Spontaneous,2024-06-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - 48mg - Subcutaneous use]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - 400mg - Oral use]),<BR><BR>[ENOXAPARIN] (C - Product used for unknown indication - n/a - [n/a - 4000[iU] - Subcutaneous use]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 30mg - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - 30mg - Oral use]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral use]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - 960mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017498120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017501100,Spontaneous,2024-06-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Cytokine release syndrome (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage III - Dose not changed - [1d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma stage III - Drug withdrawn - [9d - 20mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage III - Dose not changed - [n/a - n/a - Intravenous use])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [15d - n/a - n/a]),<BR><BR>TWYNSTA [AMLODIPINE, TELMISARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISULEPIN HYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[CLARITHROMYCIN, OMEPRAZOLE, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXAMETHASONE, DEXAMETHASONE DISODIUM PHOSPHATE, DEXAMETHASONE PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [17d - n/a - n/a]),<BR><BR>[DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, PARACETAMOL, PARACETAMOL, ACETYLSALICYLIC ACID, CAFFEINE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE, MIRTAZAPINE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [164d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017501100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017501122,Spontaneous,2024-06-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,COVID-19 (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage IV - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma stage IV - Unknown - [21d - 10mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage IV - Unknown - [22d - 375mg/m2 - Intravenous use])","ACCOFIL [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TADALAFIL [TADALAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN POTASSIUM] (C - Rhinitis - n/a - ),<BR><BR>[SULFAMETHOXAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017501122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017501535,Spontaneous,2024-06-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (205d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage IV - Drug withdrawn - [132d - 48mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage IV - Unknown - [57d - 555mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (S - Follicular lymphoma stage IV - Unknown - [1d - 70mg/m2 - Intravenous use - More in ICSR])","FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>PEGFILGRASTIM [PEGFILGRASTIM] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - ),<BR><BR>[BETAMETHASONE] (C - n/a - n/a - [n/a - 4mg - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [122d - n/a - n/a - More in ICSR]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE, CIPROFLOXACIN LACTATE] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOXIFLOXACIN] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1g - n/a]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [39d - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017501535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017473731,Spontaneous,2024-06-06 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"General physical health deterioration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Fatal - Results in Death),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Paraparesis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Fatal - Results in Death)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017473731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017468175,Spontaneous,2024-06-05 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cytokine release syndrome (n/a - Recovered/Resolved - ),<BR><BR>Diffuse large B-cell lymphoma (n/a - Not Recovered/Not Resolved - )",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [84d - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017468175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017449426,Spontaneous,2024-06-01 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Neoplasm progression (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",TEPKINLY [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017449426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017442982,Spontaneous,2024-05-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Atrial fibrillation (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cytokine release syndrome (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","DOXORUBICIN HYDROCHLORIDE [DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage III - Dose not changed - [1d - 50mg/m2 - Intravenous use]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage III - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage III - Dose not changed - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage III - Dose not changed - [1d - 750mg/m2 - Intravenous use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - Diffuse large B-cell lymphoma stage III - Drug withdrawn - [1d - 80mg - Intravenous use]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - Prophylaxis - n/a - [6d - 80mg - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage III - Dose not changed - [4d - 100mg - Oral use]),<BR><BR>[VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage III - Drug withdrawn - [1d - 1.45mg/m2 - Intravenous use])","ACCOFIL [FILGRASTIM] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, LISINOPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISULEPIN HYDROCHLORIDE] (C - Premedication - n/a - [15d - 1mg - Intravenous use - More in ICSR]),<BR><BR>[DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, PARACETAMOL, PARACETAMOL, ACETYLSALICYLIC ACID, CAFFEINE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE] (C - Premedication - n/a - [15d - 1000mg - Oral use - More in ICSR]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GRANISETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NADROPARIN, NADROPARIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Premedication - n/a - [1d - 8mg - Intravenous use]),<BR><BR>[OXAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, TRAMADOL, TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL ARGININE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[PREDNISONE] (C - Prophylaxis - n/a - [17d - 1000{DF} - n/a - More in ICSR]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017442982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017433939,Spontaneous,2024-05-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Erysipelas (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - n/a - Subcutaneous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [70d - 750mg/m2 - Intravenous use]),<BR><BR>[FUROSEMIDE] (S - n/a - Dose not changed - [n/a - n/a - n/a])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>INSULIN ASPART [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017433939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017418276,Spontaneous,2024-05-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Diffuse large B-cell lymphoma (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017418276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017419240,Spontaneous,2024-05-28 00:00:00,Healthcare Professional,European Economic Area,"Subileau M, Sarkozy C. Lymphome B diffus a grandes cellules R/R et anticorps bispecifiques : un nouvel espoir a l ere de l immunotherapie Diffuse large-cell B lymphoma R/R and bispecific antibodies: new hope in the era of immunotherapy. Immunite et cancer, Rev Immun Cancer 2023; 7 (4): 189-95.",65-85 Years,Elderly,No,Male,"Decreased appetite (n/a - Unknown - ),<BR><BR>Disease progression (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malnutrition (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - )","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 25mg - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 1400mg - n/a]),<BR><BR>TAFASITAMAB [TAFASITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 1.2mg/m2 - n/a]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 400mg/m2 - n/a]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 25mg/m2 - n/a]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 60mg - n/a]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 1mg - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017419240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017419424,Spontaneous,2024-05-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cytokine release syndrome (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - .16mg - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma, Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 750mg/m2 - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 50mg/m2 - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [4d - 100mg - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 1.4mg/m2 - Intravenous use])","DESLORATADINE [DESLORATADINE] (C - n/a - n/a - [1d - 10mg - n/a]),<BR><BR>ENTECAVIR [ENTECAVIR] (C - n/a - n/a - [268d - n/a - n/a]),<BR><BR>NIVESTIM [FILGRASTIM] (C - n/a - n/a - [22d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [3y - n/a - n/a]),<BR><BR>[ALFUZOSIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [142d - n/a - n/a]),<BR><BR>[BETAMETHASONE] (C - n/a - n/a - [400d - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [291d - n/a - n/a]),<BR><BR>[FELODIPINE] (C - n/a - n/a - [3y - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE ANHYDROUS, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [29d - n/a - n/a]),<BR><BR>[NALOXONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, NALOXONE, OXYCODONE, OXYCODONE HYDROCHLORIDE, NALOXONE, OXYCODONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE DIHYDRATE] (C - n/a - n/a - [96d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [264d - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [58d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - 1000mg - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [15d - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [4y - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [271d - n/a - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - [265d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017419424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017413469,Spontaneous,2024-05-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Diffuse large B-cell lymphoma (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017413469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017403671,Spontaneous,2024-05-24 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Cytokine release syndrome (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017403671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017405474,Spontaneous,2024-05-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hyperthermia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",TEPKINLY 48 MG SOLUTION FOR INJECTION [EPCORITAMAB] (S - Diffuse large B-cell lymphoma refractory - Not applicable - [1d - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017405474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017395261,Spontaneous,2024-05-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Erysipelas (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [70d - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [70d - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [70d - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [5d - 100mg - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [70d - n/a - Intravenous use])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [15d - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>INSULIN ASPART [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[DEXAMETHASONE, DEXAMETHASONE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - ),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017395261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017386224,Spontaneous,2024-05-21 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Confusional state (n/a - Unknown - ),<BR><BR>Disease progression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017386224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017358770,Spontaneous,2024-05-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dyspnoea (n/a - Fatal - Results in Death),<BR><BR>Oxygen saturation decreased (n/a - Fatal - Results in Death)",TEPKINLY [EPCORITAMAB] (S - B-cell lymphoma - Drug withdrawn - [n/a - 1{DF} - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017358770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017351620,Spontaneous,2024-05-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Retinal artery occlusion (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [1d - n/a - n/a]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BORIC ACID, BORAX, BORIC ACID, SODIUM BORATE, SODIUM TETRABORATE CRYST., SODIUM TETRABORATE CRYST., BORIC ACID] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM BROMIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE ACETATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[RETINOL] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017351620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017352634,Spontaneous,2024-05-15 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017352634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017353145,Spontaneous,2024-05-15 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Disease progression (n/a - Unknown - Other Medically Important Condition),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017353145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017326595,Spontaneous,2024-05-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Clostridium difficile colitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - n/a - [n/a - n/a - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Neoplasm malignant - Not applicable - [106d - n/a - n/a]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Neoplasm malignant - Not applicable - [106d - n/a - n/a]),<BR><BR>[ETOPOSIDE] (S - Neoplasm malignant - Not applicable - [106d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Chronic gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Essential tremor - n/a - [n/a - n/a - n/a]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Cytokine release syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Cytokine release syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Antifungal prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017326595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017317701,Spontaneous,2024-05-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Disease progression (n/a - Fatal - Results in Death),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous use]),"BRIVARACETAM [BRIVARACETAM] (C - Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - Premedication - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[LACOSAMIDE] (C - Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>[LAMOTRIGINE] (C - Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PHENYTOIN] (C - Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM] (C - Pyrexia - n/a - [n/a - n/a - Intravenous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017317701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017318135,Spontaneous,2024-05-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cytomegalovirus infection (94d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cytomegalovirus test positive (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma, Follicular lymphoma stage IV - Drug withdrawn - [108d - .16mg - n/a - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Product used for unknown indication - Drug withdrawn - [119d - 375mg - n/a - More in ICSR]),<BR><BR>[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (S - Follicular lymphoma, Follicular lymphoma stage IV, Product used for unknown indication - Drug withdrawn - [10d - 90mg/m2 - n/a - More in ICSR])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Product used for unknown indication - Unknown - [1d - n/a - n/a - More in ICSR]),<BR><BR>PRAMIPEXOLE [PRAMIPEXOLE, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - Prophylaxis - Unknown - [2d - n/a - n/a - More in ICSR]),<BR><BR>[AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID] (C - Product used for unknown indication - Unknown - [2d - n/a - n/a]),<BR><BR>[AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE] (C - Prophylaxis - Unknown - [2d - n/a - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Prophylaxis - Unknown - [1d - n/a - n/a]),<BR><BR>[AMOXICILLIN, CLAVULANIC ACID] (C - Prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[AMOXICILLIN, CLAVULANIC ACID] (C - Prophylaxis - n/a - [2d - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - Prophylaxis - Unknown - [10d - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[CLAVULANIC ACID] (C - Prophylaxis - Unknown - [2d - n/a - n/a - More in ICSR]),<BR><BR>[CLEMASTINE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[DAPSONE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 3350] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - Unknown - [30d - n/a - n/a - More in ICSR]),<BR><BR>[METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [30d - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (C - Product used for unknown indication - n/a - [30d - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Prophylaxis - Unknown - [1d - 80mg - n/a - More in ICSR]),<BR><BR>[METOCLOPRAMIDE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[MICONAZOLE] (C - Product used for unknown indication - Unknown - [81d - n/a - n/a - More in ICSR]),<BR><BR>[MICONAZOLE] (C - Product used for unknown indication - Unknown - [82d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - Unknown - [7d - n/a - n/a - More in ICSR]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[PIPERACILLIN SODIUM] (C - Prophylaxis - n/a - [2d - n/a - n/a]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - Prophylaxis - Unknown - [1d - n/a - n/a - More in ICSR]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017318135&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017291961,Spontaneous,2024-05-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cytokine release syndrome (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rhinovirus infection (n/a - Unknown - )","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Drug withdrawn - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Unknown - [16d - 20mg - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Drug withdrawn - [135d - 375mg/m2 - Intravenous use - More in ICSR])","[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - 800mg - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - n/a - n/a - ),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - n/a - [15d - 80mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [15d - 1g - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017291961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017286742,Spontaneous,2024-05-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Procalcitonin increased (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Septic shock (n/a - Fatal - Results in Death, Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [22d - n/a - Subcutaneous use]),"ENTECAVIR [ENTECAVIR] (C - Product used for unknown indication - n/a - [n/a - .5mg - n/a]),<BR><BR>[ACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - 400mg - n/a]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 300mg - n/a]),<BR><BR>[ATOVAQUONE] (C - Product used for unknown indication - n/a - [n/a - 5mL - n/a]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 5mg - n/a]),<BR><BR>[MAGNESIUM, MAGNESIUM CARBONATE, MAGNESIUM PIDOLATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - 40mg - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - .4mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017286742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017269330,Spontaneous,2024-04-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (n/a - Recovering/Resolving - ),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Recovering/Resolving - Other Medically Important Condition)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017269330&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017259904,Spontaneous,2024-04-29 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death),EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017259904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017250628,Spontaneous,2024-04-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose increased - [n/a - 48mg - Subcutaneous use - More in ICSR]),"[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - 5000[iU] - n/a]),<BR><BR>[DUTASTERIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[MIRTAZAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[OXAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - 1g - n/a]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017250628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017257700,Spontaneous,2024-04-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pneumonia (11d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Drug withdrawn - [1d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[CARBOPLATIN] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - n/a - Intravenous use])","DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>MELATONIN [MELATONIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SILODOSIN [SILODOSIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLCYSTEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[BEMIPARIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [33d - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE] (C - n/a - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>[DEXCHLORPHENIRAMINE] (C - n/a - n/a - [33d - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[LORMETAZEPAM] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[MAGNESIUM SULFATE] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[MESNA] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[METAMIZOLE] (C - n/a - n/a - [11d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [12d - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [8d - n/a - n/a]),<BR><BR>[SODIUM CHLORIDE, GLUCOSE MONOHYDRATE] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017257700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017247101,Spontaneous,2024-04-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Device related infection (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma - n/a - [69d - 1{DF} - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017247101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017235655,Spontaneous,2024-04-24 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Diffuse large B-cell lymphoma (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Unknown - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017235655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017230701,Spontaneous,2024-04-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diffuse large B-cell lymphoma (n/a - Unknown - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017230701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017231801,Spontaneous,2024-04-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bronchitis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 375mg/m2 - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - 750mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [1d - 50mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [5d - 100mg - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - Dose not changed - [n/a - 1.4mg/m2 - Intravenous use])","HYQVIA [HUMAN NORMAL IMMUNOGLOBULIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYGEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1g - n/a - More in ICSR]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [6d - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017231801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017201955,Spontaneous,2024-04-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Thrombocytopenia (16d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [1d - .8mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [1d - 800mg/m2 - Intravenous use]),<BR><BR>[CARBOPLATIN] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [1d - 500mg/m2 - Intravenous use]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [3d - n/a - Intravenous use]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [2d - n/a - Intravenous use])","ARANESP [DARBEPOETIN ALFA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [14d - n/a - n/a]),<BR><BR>INHIXA [ENOXAPARIN SODIUM] (C - n/a - n/a - [111d - n/a - n/a]),<BR><BR>PALONOSETRON [PALONOSETRON] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>PELGRAZ [PEGFILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE, BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFALEXIN] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[CEFUROXIME] (C - n/a - n/a - [4d - n/a - n/a]),<BR><BR>[DEXAMETHASONE] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - Premedication - n/a - [8d - 50mg - Oral use]),<BR><BR>[HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - Premedication - n/a - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN, IBUPROFEN SODIUM DIHYDRATE] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 4000] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, GLUCOSE MONOHYDRATE, SODIUM ACETATE TRIHYDRATE, SODIUM GLUCONATE, MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM ACETATE TRIHYDRATE, SODIUM GLUCONATE] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE ANHYDROUS, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Premedication - n/a - [8d - 1mg - Oral use - More in ICSR]),<BR><BR>[PARACETAMOL, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Premedication - n/a - [n/a - 1000mg - Oral use - More in ICSR]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Premedication - n/a - [4d - 100mg - Oral use - More in ICSR]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [3d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017201955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017197431,Spontaneous,2024-04-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytokine release syndrome (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose increased - [1d - .16mg - Subcutaneous use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017197431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017188217,Spontaneous,2024-04-16 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (n/a - Unknown - Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017188217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017174839,Spontaneous,2024-04-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - ),<BR><BR>Neutropenia (n/a - Not Recovered/Not Resolved - )",TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017174839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017167176,Spontaneous,2024-04-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Thrombocytopenia (17d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage II - Dose not changed - [1d - .16mg - Subcutaneous use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage II - Unknown - [43d - 375mg/m2 - Intravenous use]),<BR><BR>[CARBOPLATIN] (S - Diffuse large B-cell lymphoma stage II - Unknown - [1d - n/a - Intravenous use - More in ICSR]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma stage II - Unknown - [3d - 100mg/m2 - Intravenous use - More in ICSR]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma stage II - Unknown - [1y - 5000mg/m2 - Intravenous use - More in ICSR])","ALOXI [PALONOSETRON, PALONOSETRON HYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>ARANESP [DARBEPOETIN ALFA] (C - n/a - n/a - [63d - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [2d - 7.5mg - Oral use - More in ICSR]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Prophylaxis - n/a - [1d - 15mg - Oral use]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [3d - 15mg - Oral use - More in ICSR]),<BR><BR>INHIXA [ENOXAPARIN SODIUM] (C - n/a - n/a - [17d - n/a - n/a]),<BR><BR>PELGRAZ [PEGFILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR] (C - n/a - n/a - [7d - n/a - n/a]),<BR><BR>[BECLOMETASONE, BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFALEXIN] (C - n/a - n/a - [34d - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Premedication - n/a - [n/a - 10mg - Oral use]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [15d - 10mg - Oral use]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 4000] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS, MEROPENEM TRIHYDRATE] (C - n/a - n/a - [18d - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE ANHYDROUS, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - 1g - Oral use - More in ICSR]),<BR><BR>[PARACETAMOL] (C - Premedication - n/a - [n/a - 1g - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [148d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Prophylaxis - n/a - [4d - 100mg - n/a]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [36d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017167176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017170085,Spontaneous,2024-04-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Sudden death (1d - Fatal - Results in Death),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma refractory - Not applicable - [1d - .16mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017170085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017158279,Spontaneous,2024-04-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash erythematous (n/a - Recovering/Resolving - ),"EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma - n/a - [n/a - 1{DF} - Subcutaneous use]),<BR><BR>[LEVOFLOXACIN] (S - Prostatitis - Drug withdrawn - [10d - 500mg - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017158279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017145497,Spontaneous,2024-04-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Impetigo (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neutropenia (5d - Recovered/Resolved - Other Medically Important Condition)",EPCORITAMAB [EPCORITAMAB] (S - High-grade B-cell lymphoma - Drug withdrawn - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017145497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017145498,Spontaneous,2024-04-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Hepatocellular injury (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (17d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Tumour lysis syndrome (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - Richter's syndrome - Drug withdrawn - [n/a - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017145498&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017135549,Spontaneous,2024-04-05 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Liver disorder (n/a - Fatal - Results in Death),<BR><BR>Renal impairment (n/a - Fatal - Results in Death)",EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Not applicable - [n/a - .8mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017135549&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017069137,Spontaneous,2024-03-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Febrile neutropenia (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [1d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - Dose not changed - [1d - 375mg/m2 - Intravenous use]),<BR><BR>[CARBOPLATIN] (S - Diffuse large B-cell lymphoma - Dose not changed - [1d - n/a - Intravenous use]),<BR><BR>[ETOPOSIDE] (S - Diffuse large B-cell lymphoma - Dose not changed - [3d - 100mg/m2 - Intravenous use]),<BR><BR>[IFOSFAMIDE] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - 5mg/m2 - Intravenous use])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>AUTOLOGOUS SERUM [AUTOSERUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - n/a - n/a - [1d - 12mg - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - ),<BR><BR>[CARMELLOSE SODIUM, HYPROMELLOSE, GLYCEROL, MACROGOL 400, POLY(VINYL ALCOHOL), PROPYLENE GLYCOL, VASELINE, LIQUID PARAFFIN] (C - n/a - n/a - ),<BR><BR>[DEXCHLORPHENIRAMINE] (C - n/a - n/a - [1d - 5mg - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [1d - 1000mg - n/a - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017069137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017042628,Spontaneous,2024-03-21 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Neutropenia (n/a - Unknown - ),EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017042628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017021724,Spontaneous,2024-03-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pyrexia (2d - Recovered/Resolved - ),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma refractory - Unknown - [n/a - 48mg - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017021724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017016294,Spontaneous,2024-03-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Bronchitis (1wk - Recovered/Resolved - ),TEPKINLY 48 MG SOLUTION FOR INJECTION [EPCORITAMAB] (S - B-cell lymphoma - Not applicable - [n/a - n/a - Subcutaneous use]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ENTECAVIR [ENTECAVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NEFOPAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017016294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10017003936,Spontaneous,2024-03-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Death (n/a - Fatal - Results in Death),<BR><BR>Drug ineffective (n/a - Unknown - )",EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma refractory - Not applicable - [n/a - .16mg - Subcutaneous use]),"CYTARABINE [CYTARABINE] (C - Diffuse large B-cell lymphoma refractory - n/a - [n/a - n/a - n/a]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE] (C - Diffuse large B-cell lymphoma refractory - n/a - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (C - Diffuse large B-cell lymphoma refractory - n/a - [n/a - n/a - n/a]),<BR><BR>TOCILIZUMAB [TOCILIZUMAB] (C - Product used for unknown indication - n/a - [1d - 600mg - Intravenous use]),<BR><BR>[CARBOPLATIN] (C - Diffuse large B-cell lymphoma refractory - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10017003936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016998317,Spontaneous,2024-03-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Eosinophilia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",TEPKINLY 4 MG/0.8 ML CONCENTRATE FOR SOLUTION FOR INJECTION [EPCORITAMAB] (S - B-cell lymphoma - Not applicable - [1d - 48mg - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016998317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016969323,Spontaneous,2024-03-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amnesia (n/a - Recovering/Resolving - ),<BR><BR>Confusional state (n/a - Not Recovered/Not Resolved - ),<BR><BR>Discharge (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fear (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hospitalisation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Incoherent (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Memory impairment (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sepsis (n/a - Fatal - Results in Death),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )",TEPKINLY [EPCORITAMAB] (S - Non-Hodgkin's lymphoma recurrent - Drug withdrawn - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016969323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016896686,Spontaneous,2024-02-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cytokine release syndrome (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Intentional product use issue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumocystis jirovecii pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma, Follicular lymphoma - Drug withdrawn - [1d - n/a - n/a - More in ICSR]),<BR><BR>EPCORITAMAB [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - B-cell lymphoma, Follicular lymphoma - Dose not changed - [n/a - .16mg - n/a - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Drug withdrawn - [16d - 20mg - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma, Follicular lymphoma - Not applicable - [n/a - 375mg/m2 - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma, Follicular lymphoma - Unknown - [n/a - n/a - n/a])","EXFORGE [VALSARTAN, AMLODIPINE, VALSARTAN, AMLODIPINE BESILATE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>JANUMET [METFORMIN HYDROCHLORIDE, SITAGLIPTIN, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE, METFORMIN, SITAGLIPTIN] (C - Product used for unknown indication - Unknown - [3d - n/a - n/a - More in ICSR]),<BR><BR>METFORMIN HYDROCHLORIDE, SITAGLIPTIN [METFORMIN HYDROCHLORIDE, SITAGLIPTIN] (C - Product used for unknown indication - Unknown - [3d - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - Unknown - [28d - 1{DF} - n/a - More in ICSR]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - Product used for unknown indication - Unknown - [245d - 1{DF} - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - Unknown - [14d - 10mg - n/a - More in ICSR]),<BR><BR>[DALTEPARIN SODIUM] (C - Product used for unknown indication - Unknown - [54d - 1{DF} - n/a]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - Unknown - [2d - n/a - n/a]),<BR><BR>[LACTULOSE] (C - Product used for unknown indication - Unknown - [9d - 1{DF} - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - Unknown - [3d - 1{DF} - n/a]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - Unknown - [1d - n/a - n/a]),<BR><BR>[PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a - More in ICSR]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - Unknown - [15d - n/a - n/a - More in ICSR]),<BR><BR>[PREDNISOLONE] (C - Prophylaxis - Unknown - [6d - 100mg - n/a]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - Unknown - [1d - n/a - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Unknown - [343d - 1{DF} - n/a]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - Unknown - [343d - 1{DF} - n/a - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016896686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016891632,Spontaneous,2024-02-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Diffuse large B-cell lymphoma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),TEPKINLY [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - Unknown - [n/a - 4mg - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016891632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016819144,Spontaneous,2024-02-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - ),<BR><BR>COVID-19 pneumonia (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (11d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Unknown - [1d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Dose not changed - [n/a - 20mg - Oral use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Unknown - [n/a - 712.5mg - Intravenous use])","INSULIN LISPRO [INSULIN LISPRO] (C - Diabetes mellitus - n/a - [n/a - 10[iU] - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Prophylaxis - n/a - [n/a - 80mg - n/a]),<BR><BR>[CALCIUM FOLINATE] (C - Prophylaxis - n/a - [n/a - 15mg - n/a]),<BR><BR>[FLUCONAZOLE] (C - Antifungal prophylaxis - n/a - [n/a - 200mg - n/a]),<BR><BR>[INSULIN GLARGINE] (C - Diabetes mellitus - Unknown - ),<BR><BR>[NEBIVOLOL] (C - Hypertension - n/a - [n/a - 5mg - n/a]),<BR><BR>[PARACETAMOL] (C - Premedication - Unknown - ),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Dyslipidaemia - n/a - [n/a - 10mg - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Prophylaxis - n/a - [n/a - 960mg - n/a]),<BR><BR>[VALACICLOVIR] (C - Prophylaxis - n/a - [n/a - 500mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016819144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016805242,Spontaneous,2024-02-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma - Unknown - [n/a - n/a - Subcutaneous use]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma - Unknown - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma - Unknown - [n/a - n/a - Intravenous use])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016805242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016807298,Spontaneous,2024-02-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Cytokine release syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Immune effector cell-associated neurotoxicity syndrome (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma stage IV - Dose not changed - [20d - n/a - Subcutaneous use]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ENTECAVIR [ENTECAVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NEFOPAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016807298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016792714,Spontaneous,2024-02-09 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (15d - Recovered/Resolved - ),<BR><BR>Pyrexia (15d - Recovered/Resolved - )",TEPKINLY [EPCORITAMAB] (S - Product used for unknown indication - Unknown - [n/a - .16mg - Subcutaneous use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016792714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016686138,Spontaneous,2024-01-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cytokine release syndrome (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Pneumocystis jirovecii pneumonia (n/a - Unknown - Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - B-cell lymphoma, Follicular lymphoma - Drug withdrawn - [1d - .8mg - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - B-cell lymphoma, Follicular lymphoma - Drug withdrawn - [15d - 20mg - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - B-cell lymphoma, Follicular lymphoma - Drug withdrawn - [n/a - 375mg/m2 - Intravenous use - More in ICSR])","EXFORGE [VALSARTAN, AMLODIPINE, VALSARTAN, AMLODIPINE BESILATE] (C - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),<BR><BR>JANUMET [METFORMIN HYDROCHLORIDE, SITAGLIPTIN, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE, METFORMIN, SITAGLIPTIN] (C - Product used for unknown indication - Dose not changed - [3d - n/a - n/a - More in ICSR]),<BR><BR>METFORMIN HYDROCHLORIDE, SITAGLIPTIN [METFORMIN HYDROCHLORIDE, SITAGLIPTIN] (C - Product used for unknown indication - Unknown - [3d - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - Unknown - [28d - n/a - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - Product used for unknown indication - Unknown - [245d - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - Unknown - [15d - n/a - n/a - More in ICSR]),<BR><BR>[DALTEPARIN SODIUM] (C - Product used for unknown indication - Unknown - [54d - n/a - n/a - More in ICSR]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - Unknown - [2d - n/a - n/a]),<BR><BR>[LACTULOSE] (C - Product used for unknown indication - Unknown - [9d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - Unknown - [1d - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - Unknown - [21d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Prophylaxis - Unknown - [3d - 100mg - n/a - More in ICSR]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - Unknown - [2d - n/a - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - Product used for unknown indication - Dose not changed - [77d - n/a - n/a - More in ICSR]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Dose not changed - [343d - n/a - n/a]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - Dose not changed - [343d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016686138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016663185,Spontaneous,2024-01-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abnormal faeces (n/a - Unknown - ),<BR><BR>Asthma (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - ),<BR><BR>Faeces discoloured (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sputum discoloured (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - n/a - [78d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - n/a - [64d - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Not applicable - [64d - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - n/a - [64d - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - n/a - [68d - n/a - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - n/a - [43d - n/a - Intravenous use])","PEGFILGRASTIM [PEGFILGRASTIM] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN SODIUM, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - Influenza like illness - n/a - [7d - n/a - n/a]),<BR><BR>[CLEMASTINE] (C - Allergy prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM, SALBUTAMOL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrointestinal disorder prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Antifungal prophylaxis - n/a - [97d - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [97d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016663185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016648297,Spontaneous,2024-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Unknown - ),<BR><BR>COVID-19 pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Escherichia infection (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypoxia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Neutropenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma stage IV - n/a - [85d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma stage IV - n/a - [114d - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma stage IV - Not applicable - [114d - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma stage IV - n/a - [114d - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma stage IV - n/a - [118d - n/a - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma stage IV - n/a - [114d - n/a - Intravenous use])","BINOCRIT [EPOETIN ALFA] (C - Anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>NUSTENDI [EZETIMIBE, BEMPEDOIC ACID] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrointestinal disorder prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Infection prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - Psychiatric disorder prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ENOXAPARIN SODIUM] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOCETIRIZINE, LEVOCETIRIZINE DIHYDROCHLORIDE] (C - Premedication - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE ANHYDROUS, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Anxiety, Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Pain prophylaxis, Premedication - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM, TRIMETHOPRIM LACTATE, SULFAMETHOXAZOLE] (C - Infection prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016648297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016619151,Spontaneous,2024-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - n/a - [1d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - n/a - [1d - n/a - Oral use - More in ICSR]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Intravenous use])","XERISTAR [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Mixed anxiety and depressive disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - Mixed anxiety and depressive disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Type V hyperlipidaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016619151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016608249,Spontaneous,2024-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,COVID-19 (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"EPCORITAMAB [EPCORITAMAB] (S - Follicular lymphoma stage III - Dose not changed - [1d - n/a - Subcutaneous use - More in ICSR]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Follicular lymphoma stage III - Unknown - [21d - 15mg - Oral use - More in ICSR]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Follicular lymphoma stage III - Unknown - [15d - n/a - Intravenous use - More in ICSR])","[DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE, FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016608249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016595911,Spontaneous,2024-01-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Leukopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","EPCORITAMAB [EPCORITAMAB] (S - Diffuse large B-cell lymphoma - n/a - [64d - n/a - Subcutaneous use]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Intravenous use]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Diffuse large B-cell lymphoma - Dose not changed - [n/a - n/a - Intravenous use]),<BR><BR>[PREDNISONE] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Oral use]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (S - Diffuse large B-cell lymphoma - n/a - [n/a - n/a - Intravenous use])","DEXAMETHASONE [DEXAMETHASONE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>POSACONAZOLE [POSACONAZOLE] (C - Antifungal prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM FOLINATE] (C - Drug toxicity prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[LACTULOSE] (C - Constipation prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrointestinal disorder prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMETHOPRIM] (C - Antifungal prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016595911&_xpt=1&_xf=pdf"">ICSR</a>"